
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SAGE market cap is 445.74M. The company's latest EPS is USD -6.5169 and P/E is -1.12.
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 77.97M | 7.9M | 8.65M | 11.87M | 12.82M |
Operating Income | -42.07M | -117.68M | -111.3M | -101.2M | -102.19M |
Net Income | -32.71M | -108.48M | -102.85M | -93.55M | -95.78M |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 1.11B | 6.31M | 7.69M | 86.46M | 41.24M |
Operating Income | 596.23M | -460.91M | -546.99M | -579.85M | -432.37M |
Net Income | 606.07M | -457.89M | -532.78M | -541.49M | -400.67M |
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 882.28M | 767.6M | 697.11M | 622.43M | 547.22M |
Total Liabilities | 82.75M | 61.8M | 69.04M | 70.6M | 82.13M |
Total Equity | 799.53M | 705.8M | 628.06M | 551.84M | 465.09M |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 2.16B | 1.83B | 1.36B | 882.28M | 547.22M |
Total Liabilities | 86.91M | 96.26M | 103.85M | 82.75M | 82.13M |
Total Equity | 2.07B | 1.73B | 1.25B | 799.53M | 465.09M |
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -540.59M | -37.83M | -118.27M | -200.63M | -267.19M |
Investing | 442.91M | 139.44M | 139.05M | 220.1M | 266.68M |
Financing | 6.03M | 1.56M | 9.63M | 10.67M | 10.66M |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 664.28M | -378.18M | -460.04M | -540.59M | -267.19M |
Investing | 442.68M | -1B | 325.43M | 442.91M | 266.68M |
Financing | 426.76M | 13.33M | 3.07M | 6.03M | 10.66M |
Market Cap | 445.74M |
Price to Earnings Ratio | -1.12 |
Price to Sales Ratio | 10.84 |
Price to Cash Ratio | 5.52 |
Price to Book Ratio | 0.96 |
Dividend Yield | - |
Shares Outstanding | 61.48M |
Average Volume (1 week) | 1.49M |
Average Volume (1 Month) | 1.58M |
52 Week Change | -66.73% |
52 Week High | 22.18 |
52 Week Low | 4.62 |
Spread (Intraday) | 0.15 (2.07%) |
Company Name | Sage Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.sagerx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions